View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
January 3, 2017updated 13 Jul 2022 10:12am

Ardelyx begins two clinical trials of RDX7675 to treat hyperkalemia

US-based clinical-stage company Ardelyx has begun a Phase III clinical trial and another onset-of-action clinical trial of RDX7675 to treat hyperkalemia.

US-based clinical-stage company Ardelyx has begun a Phase III clinical trial and another onset-of-action clinical trial of RDX7675 to treat hyperkalemia.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

RDX7675 is an orally administered, non-absorbed potassium-binding polymer, which binds to potassium in pharmacodynamics studies in healthy volunteers.

It has been developed as a patented improvement to sodium polystyrene sulfonate (SPS), a US Food and Drug Administration (FDA) approved polymer regarded as the standard-of-care to treat hyperkalemia.

Its composition features physical and chemical modifications to eliminate sodium and sorbitol, as well as optimise binding capacity while making the product taste pleasant.

The Phase II trial will be conducted as a randomised, single-blind, three-part study intended to test the safety and efficacy of RDX7675 while examining about 300 adult patients with hyperkalemia. The study also includes a long-term, open-label safety extension.

"The Phase III study for hyperkalemia marks the start of the fifth Phase III clinical trial from our pipeline of internally developed, gut-restricted treatments in development."

The onset-of-action trial will be carried out as a single-blind, placebo controlled study, which will test the onset-of-action, safety and efficacy of RDX7675 in 60 patients with hyperkalemia.

Ardelyx CEO Mike Raab said: "The Phase III study for hyperkalemia marks the start of the fifth Phase III clinical trial from our pipeline of internally developed, gut-restricted treatments in development.

"Hyperkalemia is a difficult to treat and potentially devastating condition in patients with chronic kidney disease and / or heart failure.

“The initiations of the Phase III and onset-of-action trials with RDX7675 are important steps forward for our cardiorenal portfolio, as we look to bring better treatments to underserved patients who are not satisfied with their current care.”

The company is expected to release data from the onset-of-action study in the first half of this year.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena